Olga Pol earned a PhD in Neurosciences (1991) from the Universitat Autònoma de Barcelona (UAB), Spain. She is currently Group Leader of the Molecular Neuropharmacology Research Group at the Sant Pau Research Institute (IR Sant Pau) and the Institute of Neuroscience (INc), UAB. She has extensive expertise in the molecular mechanisms of chronic pain and associated emotional and cognitive disorders, as well as in the development of innovative pharmacological therapies for neuropathic, nociplastic, and osteoarthritis pain. Her research integrates behavioral, pharmacological, and molecular approaches, with particular interest in oxidative stress, neuroinflammation, redox signaling, and endogenous protective pathways. She has published more than 100 articles in international journals and serves as a Section Board Member of Antioxidants (MDPI) and Review Editor of Frontiers in Pharmacology. She has Guest-Edited five Special Issues on chronic pain and oxidative stress, led nationally and internationally funded research projects, and supervised doctoral and master’s theses. Her work has contributed to advancing medicinal gases as promising therapeutic strategies for chronic pain. She also investigates strategies to enhance conventional analgesics, aiming to improve pain relief, reduce adverse effects, and ultimately improve patients’ quality of life.